Ionis Pharmaceuticals reports $32 million in TRYNGOLZA net product sales for Q3 2025
Ionis Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2025. The company recorded $32.0 million in net product sales from TRYNGOLZA (olezarsen) in the third quarter, representing nearly a 70% increase over the prior quarter. Cash, cash equivalents, and short-term investments totaled $2.2 billion as of September 30, 2025, compared to $2.3 billion on December 31, 2024. The company's working capital decreased over the same period, primarily due to the reclassification of 0% convertible notes as a current liability. Business developments during the period included the launch of TRYNGOLZA and DAWNZERA (donidalorsen), with the latter described as having an encouraging start. Ionis announced positive topline Phase 3 results for olezarsen in severe hypertriglyceridemia and for zilganersen in Alexander disease, with regulatory filings planned in the coming months. The company anticipates independent launches of olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease in 2026. Ionis increased its 2025 financial guidance, citing continued strength across its business and expects to reach cash flow breakeven in 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251029676166) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.